Dithranol in a cream preparation: disperse or dissolve?

Area of Science:

• Dermatology
• Pharmaceutics
• Cosmetic Science

Background:

• Psoriasis is a chronic inflammatory skin condition requiring effective topical treatments.
• Dithranol is a well-established treatment for psoriasis, but its formulation impacts efficacy and tolerability.
• Optimizing dithranol cream preparations is crucial for improving patient outcomes in short-contact therapy.

Purpose of the Study:

• To compare the clinical efficacy, side effects, and patient acceptance of two dithranol cream preparations (dissolved vs. dispersed) for psoriasis.
• To identify the ideal dithranol cream formulation for short-contact treatment regimens.
• To evaluate the manufacturing and cost-effectiveness of different dithranol formulations.

Main Methods:

• A double-blind, left-right comparative study involving ten patients with chronic plaque-type psoriasis.
• Treatment duration of 7 weeks using a short-contact regimen.
• Assessment of clinical efficacy (erythema, induration, scaling, PASI score), skin irritation, and patient appreciation via questionnaire.

Main Results:

• Dispersion of dithranol in cream B resulted in significantly less skin irritation and discoloration compared to dithranol dissolved in cream A.
• The clinical efficacy of the dispersed dithranol formulation was comparable to the dissolved dithranol preparation.
• The dispersed dithranol formulation demonstrated advantages in manufacturing ease, reliability, and cost-effectiveness.

Conclusions:

• Dithranol dispersed in a cream base is a superior formulation for short-contact psoriasis treatment due to reduced side effects and comparable efficacy.
• The dispersed formulation offers practical benefits including simpler manufacturing, enhanced pharmacist independence, and lower preparation costs.
• This study recommends the dispersed dithranol formulation for routine use in short-contact psoriasis therapy.